DeutschNewstral
Article
jdsupra.com on 2019-05-25 01:39
FDA Issues Final Guidance on “Considerations in Demonstrating Interchangeability With a Reference Product”
Related news
- Proving Biosimilar Interchangeability – New FDA Guidance Provides Important Considerations for Making that Proofjdsupra.com
- FDA Issues Draft Guidance On Biosimilar Licensure For Fewer Than All Conditions Licensed for Reference Productjdsupra.com
- FDA guidance may ease path to biosimilar interchangeabilityjdsupra.com
- FDA Issues Another Draft Guidance Regarding Biosimilar Interchangeabilityjdsupra.com
- FDA Finalizes Guidance on Biosimilar Interchangeability, Reiterates Case-by-Case Approach to Data Requirementsjdsupra.com
- FDA Guidance on DSCSA Product Identifier Requirementsjdsupra.com
- FDA proposes streamlining combination product regulationsjdsupra.com
- FDA Finalizes New Definition of Biological Productjdsupra.com
- FDA Issues Final Definition for “Biological Product”jdsupra.com
- A Tale of Two Studies: FDA Releases Draft Guidance on Demonstrating Efficacy with a Single Studyjdsupra.com
- FDA Postpones Foreign Inspections Through April 2020: Considerations for Industryjdsupra.com
- FDA Extends Compliance Period for Wholesalers to Verify Returned Productjdsupra.com
- FDA Requests Comments On Product User Fee Programsjdsupra.com
- FDA, FTC Warn CBD Maker Over Product Claimsjdsupra.com
- Curaleaf Responds to FDA Warning Over CBD Product Marketingjdsupra.com
- Blog: FDA Finalizes Two Guidance Documents Regarding Medical Product Communicationsjdsupra.com
- FDA Increases Scrutiny Of CBD Product Marketing Languagejdsupra.com
- FDA Issues Final Rule Amending The Definition Of “Biological Product”jdsupra.com
- FDA Releases Draft Guidance on Promotion of Biological Reference and Biosimilar Productsjdsupra.com
- U.S. Liability Considerations for Product Manufacturers Shifting Production to New Products to Assist in Pandemic Responsejdsupra.com